Title

Type I interferon responses contribute to immune protection against mycobacterial infection

Authors

Andrea Szydlo-Shein[1], Blanca Sanz-Magallón Duque de Estrada[1], Joshua Rosenheim[1], Carolin T.

Turner[1], Aneesh Chandran[1,2], Evdokia Tsaliki[1], Marc C. I. Lipman[3,4], Heinke Kunst[5], Gabriele

Pollara[1], Philip M. Elks[6], Jean-Pierre Levraud[7], Elspeth M. Payne[8], Mahdad Noursadeghi[1], Gillian S.

Tomlinson[1,9]*

Affiliations

[1]Division of Infection and Immunity, University College London, London, UK

[2]Institute of Dentistry, Queen Mary University of London, London, UK

[3]Respiratory Medicine, Royal Free London NHS Foundation Trust, London, UK

[4]UCL Respiratory, University College London, London, UK

[5]Blizard Institute, Barts and The London School of Medicine and Dentistry, Queen Mary University

of London, London, UK

[6]The Bateson Centre, School of Medicine and Population Health, The University of Sheffield,

Sheffield, UK

[7]Université Paris-Saclay, CNRS UMR9197, Institut Pasteur, Université Paris-Cité, Institut des

Neurosciences Paris-Saclay, 91400 Saclay, France

[8]Research Department of Haematology, Cancer Institute, University College London, London, UK

[9]Clinical Medicine, School of Medicine and Population Health, The University of Sheffield, Sheffield,

UK

*Corresponding author

Corresponding author

Gillian S. Tomlinson, Email: g.tomlinson@ucl.ac.uk

ABSTRACT

Type I interferon responses have been considered detrimental to host protection in tuberculosis (TB).

We provide novel data to challenge this paradigm, derived from transcriptional profiling of human in

vivo immune responses to discover associations with radiographic disease severity in pulmonary

TB, combined with mechanistic studies to test causality for observed associations using a zebrafish

larval mycobacterial infection model. Type I interferon activity in tissue samples from the site of a

standardised mycobacterial challenge, the tuberculin skin test, was associated with less severe

human TB disease. Abrogation of type I interferon signalling, by CRISPR-mediated mutagenesis of

stat2, led to increased burden and dissemination of *Mycobacterium marinum* infection in zebrafish

larvae. The mechanism for increased severity of mycobacterial infection in zebrafish involves

reduced recruitment of myeloid cells required to restrict bacterial growth. Our data support a clear

host protective role for type I interferon responses in mycobacterial infection, with potential

applications for risk-stratification of adverse outcomes and development of a host-directed therapy

to mitigate against severe disease.

KEYWORDS

Tuberculosis, mycobacterial infection, zebrafish, immune response, type I interferon, macrophage,

neutrophil, host-directed therapy

INTRODUCTION

Mycobacterium tuberculosis (Mtb) infection results in diverse clinical manifestations, ranging from asymptomatic infection to active tuberculosis (TB), which comprises an enormous spectrum of disease severity [1,2]. Although we know that immune responses contribute to the risk of disease, current understanding of the role of immune response variation in disease severity is limited. Identification of immune correlates of disease severity may offer new insights into the immune pathways that contribute to protection and pathogenesis. This is necessary to enable novel vaccine design and evaluation, stratify disease risk in people who become infected and inform development of novel host-directed therapies to shorten treatment regimens, mitigate against antimicrobial resistance, and against the chronic sequelae of tissue injury in TB [3].

To date, protective immunity has focussed on tumour necrosis factor (TNF) and type II interferon mediated immune signalling pathways [4]. Type I interferon immune responses are also pervasive in TB. Unlike the protective role of type I interferons in viral infections, the prevailing view has been that this pathway may contribute to TB pathogenesis [5]. However, causal inferences have been limited to mouse models which do not represent a natural host-pathogen interaction [6]. We sought to re-evaluate the differential role of immune signalling pathways in protection or pathogenesis in TB, by combining observational human data with genetic perturbation of immune signalling pathways in zebrafish infected with its natural pathogen *Mycobacterium marinum* (Mm).

Observational immunology in human TB is limited by reverse causality. This is particularly true for positive correlations between immune responses and disease severity. Therefore, we specifically sought to identify negative correlations with disease severity, that are less susceptible to this limitation and suggestive of protective immunity. Transcriptional profiling can be used to make unbiased system level assessment of immune signalling pathways. In patients with TB, we used transcriptional profiling to investigate steady state perturbation of the immune system in peripheral blood [7], and to measure inducible immune responses at the tissue site of a standardised Mtb challenge modelled by the tuberculin skin test (TST) [8,9]. Our innovative strategy revealed an inverse relationship between type I interferon activity in the TST transcriptome and radiographic severity of human TB, challenging the paradigm of a host-pathogenic role for type I interferons. Here, we

confirmed a role for type I interferon responses in host protection against mycobacteria by showing

that mutagenesis of *stat2* to abrogate downstream type I interferon signalling, led to increased

severity of *M. marinum* infection in zebrafish larvae, due to reduced recruitment of macrophages and

neutrophils required to contain bacterial growth.

RESULTS

Immune pathways negatively correlated with TB disease severity are not evident in the steady

state peripheral blood transcriptome

Our analysis of human immune responses in TB leveraged a previously reported cohort of patients

with pulmonary TB [10] which we have extended to a total sample size of 51 people with

microbiologically confirmed disease, within one month of commencing anti-tuberculous

chemotherapy (Table 1, Figure S1). We evaluated disease severity using a published radiographic

scoring system which incorporates extent of disease and the presence of cavitation on chest x-ray [11].

We performed genome-wide transcriptional profiling of peripheral blood, and punch biopsies from

the site of a 48 hour TST. Transcriptional changes associated with the immune response to TB were

identified by comparison with reference healthy control blood samples and punch biopsies from the

site of control saline injections. We used outlier profile analysis [12] to capture inter-individual variation

in immune perturbation associated with active TB. This overcomes the limitation of conventional

differential gene expression analysis that may exclude changes that occur in only a subset of cases.

In outlier profile analysis, we identified transcripts in the peripheral blood of each individual that were

significantly enriched (more abundant) compared to control blood samples from healthy volunteers.

The integrated list of outlier genes from the entire cohort defined an active TB blood transcriptome

comprised of 2620 genes, enriched for pathways involved in innate and adaptive immune responses

and cell cycle regulation (Figure S2).

Next, we sought to identify immunological pathways correlated with disease severity. We identified

individual genes in the blood transcriptome that showed statistically significant correlations with the

radiographic severity score (Figure 1A). Pathway analysis revealed no enrichment at pathway level

among genes negatively correlated with TB severity. There was modest enrichment for innate and

adaptive immune response pathways among genes positively correlated with radiographic disease

score (Figure 1B). Next, we subjected these genes to Ingenuity Pathway Analysis (IPA) upstream

regulator analysis to collate groups of co-regulated genes (Figure 1A and Figure S3A). These were

annotated by their upstream regulators at the level of cytokines, transmembrane receptors, kinases

and transcriptional regulators, representing the key components of signalling pathways which

mediate immune responses. To provide increased confidence that these modules represented co-

regulated genes in each molecular pathway, we retained only those that had significantly greater co-

correlated expression than modules of genes randomly selected from our blood transcriptomes [13].

Only six gene modules were identified among genes negatively correlated with disease severity, but

these did not represent obvious coordinated biology (Figure S3B). Among genes positively

correlated with TB severity 94 gene modules were identified, reflecting pro-inflammatory cytokine

activity, type II interferon and T cell activation and innate immune signalling pathways (Figure S3C

and Figure 1C).

Outlier analysis of the TST transcriptome defines inducible human in vivo immune responses

in active tuberculosis

We repeated the same analysis of the dynamic response to TST challenge in the same patient

cohort. In this analysis, we identified transcripts in the TST of each individual that were significantly

enriched compared to gene expression in control data from skin biopsies at the site of saline

injections. The integrated list of outlier genes statistically enriched in TST samples from all 51

individuals compared to control saline samples defined an active TB TST transcriptome comprised

of 3222 transcripts. This analysis revealed that although some aspects of the TST response are

consistent in all people, there is also considerable variability between individuals (Figure S4A). The

3222 transcripts identified by this approach, were enriched for canonical pathways involved in cell

mediated responses, consistent with our previous description of the TST gene signature identified

by conventional differential gene expression analysis [9,10] (Figure S4B).

Reduced type I interferon activity in the TST transcriptome is associated with increased

severity of human TB disease

In contrast to the peripheral blood analysis, pathway analysis of individual genes in the TST

transcriptome that showed statistically significant correlations with the radiographic severity score

identified enrichment for cell mediated immune responses among genes negatively correlated with

disease severity. Statistically less significant enrichment for immune response pathways was evident

among genes positively correlated with TB severity (Figure 2A and Figure S5A). Subsequent IPA

upstream regulator analysis identified 111 modules among genes inversely correlated with

radiographic TB severity, suggesting they may contribute to host protection against severe disease

(Figure 2A-C and Figure S5B). These included transcriptional modules representing pro-

inflammatory cytokine activity, interferon gamma and T cell activity, consistent with existing evidence

predominantly supporting their protective roles in TB [4] (Figure 2B). In addition, we found enrichment

of multiple co-regulated gene networks attributed to type I interferon signalling, suggesting that type

I interferon responses may also contribute to host protection in mycobacterial infection (Figure 2B,

C). Interferon gamma was also predicted to regulate one of only two small putative networks within

genes positively correlated with disease severity; the other driven by TCL1A, an AKT kinase activator

that promotes cellular survival [14] (Figure S5C).

To validate the immunological responses predicted to be associated with disease severity by

upstream regulator analysis, we quantified the expression of two independently derived and largely

non-overlapping type I interferon inducible gene modules reflecting the specific biological activity of

type I interferons (Table S1) [9,10], within the TB TST transcriptome (Figure 2D). This provided

independent validation of the inverse relationship between type I interferon responses and

radiographic severity of TB (Figure 2E), suggestive of a host-protective role. By contrast, the

expression of the entire TST transcriptome and that of three distinct independently derived modules

specific for interferon gamma inducible genes [9] (Table S1) did not correlate with disease severity

(Figure S6A-E). There was also no relationship between peripheral blood type I IFN activity and

radiological severity score (Figure S6F, G).

150 ***stat2* CRISPant zebrafish larvae exhibit increased susceptibility to *M. marinum* infection**

151 The finding of numerous modules pertaining to type I interferon signalling among TST transcriptome

152 genes negatively correlated with disease severity prompted us to test the role of this pathway in

153 mycobacterial infection experimentally. Since type I interferons are primarily induced following

154 activation of innate immune recognition pathways [15], we investigated their role in the zebrafish larval

155 *M. marinum* infection model, which allows exclusive assessment of innate immunity [16]. The

156 mammalian canonical type I interferon signalling pathway is highly conserved in zebrafish [17,18]

157 (Figure 3A). First, we confirmed that intravenous *M. marinum* infection of wild type zebrafish larvae

158 induces a type I interferon response, by showing enrichment for two distinct independently derived

159 transcriptional modules reflecting type I interferon activity [13,18] (Table S1) within genome-wide

160 transcriptomic data from whole embryos after four days of mycobacterial growth (Figure 3B, C). To

161 block downstream type I interferon signalling we used CRISPR-mediated mutagenesis of *stat2*, as

162 a critical component of the principal transcription factor complex which induces expression of type I

163 interferon stimulated genes (ISG) [19–21], for which there is a single zebrafish orthologue [17] (Figure 3A).

164 Injection of three guide RNA/Cas9 ribonucleoprotein (RNP) complexes each targeting a distinct *stat2*

165 exon, into one cell stage wild type zebrafish embryos led to >90% efficient mutagenesis in CRISPant

166 embryos, confirmed by next-generation sequencing (Figure S7A and Figure S8A). We verified loss

167 of functional downstream type I interferon signalling by showing that induction of the classical ISG

168 Mxa [18,21] by injection of recombinant Interferon phi 1 protein, measured by expression of a reporter

169 *mxa:mCherry* transgene [22], was significantly attenuated in *stat2* CRISPants compared to siblings

170 injected with "scrambled" (negative control) RNPs designed to lack genomic targets (Figure S7B and

171 Figure S8B-C). *stat2* CRISPants developed normally up to five days post-fertilisation (Figure S8B).

172 There was no difference in survival of *M. marinum* infected *stat2* CRISPants and scrambled RNP

173 injected siblings within the timeframe of our experiments (Figure 3D, E). However, mycobacterial

174 burden, the number of bacterial foci and the spatial dissemination of bacteria, determined by

175 quantitation of fluorescent foci of *M. marinum*, were all significantly higher in intravenously infected

176 *stat2* CRISPants compared to control RNP injected siblings, indicative of more severe disease

177 (Figure 3D, F-H). These findings are consistent with a host protective role for type I interferons in

178   mycobacterial infection, as suggested by our observation of an inverse relationship between type I

179   interferon activity and disease severity in human TB (Figure 2).

180   Steady state neutrophil numbers are reduced in *stat2* CRISPant zebrafish larvae

Macrophages are critically important for control of *M. marinum* infection in zebrafish larvae [23–25] and

neutrophils may also contribute to mycobacterial killing [26,27]. Therefore, to investigate the

mechanisms by which *stat2* deficiency leads to worse mycobacterial infection we used transgenic

zebrafish lines with fluorescent immune cell lineages, *Tg(mpeg1:mCherry)* [28] and *Tg(mpx:eGFP)* [29],

to generate *stat2* CRISPants that have fluorescent macrophages or neutrophils, respectively. First,

we asked whether *stat2* disruption impacted steady state macrophage or neutrophil numbers. We

demonstrated by quantitative fluorescence microscopy, using integrated fluorescence as a surrogate

for cell number, that *stat2* deficiency did not affect baseline macrophage abundance (Figure 4A, B).

However, it was associated with reduced neutrophil abundance (Figure 4C, D), a phenotype also

reported in human STAT2 deficiency [30].

191   Recruitment of macrophages but not neutrophils to the site of sterile injury is *stat2* dependent

Type I interferons have previously been shown to influence cellular migration [15,31]. Therefore, we

tested macrophage and neutrophil recruitment in *stat2* CRISPants using a tailfin transection model

of sterile injury, most commonly used to evaluate neutrophil recruitment [29] (Figure S7C). The timing

of neutrophil homing to the site of sterile tail fin transection was normal in *stat2* CRISPants, with

maximal accumulation at six hours and dissipation of recruited cells becoming evident by 24 hours,

similar to that of control RNP injected embryos (Figure 5A, B and Figure S9) and in keeping with

previous studies [29,32]. Despite baseline neutropenia, the number of neutrophils at the wound site at

the point of maximal recruitment in *stat2* CRISPants exceeded that of control RNP injected embryos.

But by 24 hours the number of neutrophils at the injury site was significantly reduced in *stat2*

CRISPants, likely reflecting the attenuated increase in total neutrophil numbers in response to the

acute inflammatory challenge (Figure 5C, D).

Macrophage recruitment to the site of a sterile tail wound has previously been reported to be slower

than that of neutrophils [32,33]. Very few macrophages were present at the tailfin transection site by

one hour in either *stat2* disrupted or control transgenic larvae, but recruitment progressively

increased until 24 hours in both groups (Figure 6). Fewer macrophages were found in the vicinity of

the wound site at all time points post-injury in *stat2* CRISPant transgenic embryos compared to

control RNP injected siblings, the majority being located outwith the tailfin (Figure 6). Taken together

these data suggest that *stat2* is necessary for macrophage recruitment but non-essential for

neutrophil recruitment to a sterile injury site. In addition, baseline neutropenia did not impact the

number of cells localised to the wound at peak neutrophil recruitment.

Recruitment of myeloid cells to the site of *M. marinum* infection is *stat2* dependent

Next we focused on macrophage recruitment to the site of mycobacterial infection because this has

been reported to be crucial for control of *M. marinum* growth in zebrafish larvae [24]. We found a

significant reduction in the number of macrophages recruited to the site of localised hindbrain

M. marinum infection in *stat2* deficient transgenic zebrafish larvae compared to their counterparts

injected with scrambled RNPs (Figure S7D and Figure 7A, B). We then evaluated whether *stat2*

disruption affected recruitment of neutrophils to the site of mycobacterial infection. We found that in

contrast to their normal peak recruitment to a sterile wound, the number of neutrophils attracted to

the site of mycobacterial disease was significantly diminished in *stat2* CRISPants (Figure 7C, D).

Collectively, these results demonstrate that myeloid cell recruitment to the site of *M. marinum*

infection is *stat2* dependent.

In total, the recruitment studies suggest that *stat2* disruption leads to a broad defect in macrophage

recruitment to both infectious and non-infectious inflammatory foci. By contrast, *stat2* is non-essential

for neutrophil migration to sterile injury. The latter finding is consistent with defective migration, rather

than neutropenia, being the principal mechanism for reduced neutrophil numbers at the site of

M. marinum infection.

DISCUSSION

We have taken an innovative approach, combining molecular and systems level evaluation of human

immune responses to a standardised experimental challenge, to identify biological pathways

associated with TB disease severity. We experimentally validated host factors responsible for

differences in phenotype using a relevant, tractable animal model which represents a natural host-

pathogen relationship [16]. Molecular interrogation of human in vivo responses to Mtb revealed that

reduced type I interferon activity within the TST transcriptome was associated with worse pulmonary

disease. Deficient type I interferon signalling, achieved by genetic disruption of *stat2*, led to more

severe mycobacterial infection in zebrafish larvae, via a mechanism involving impaired recruitment

of macrophages and neutrophils to the site of disease and reduced neutrophil numbers at baseline.

Taken together our results demonstrate an important role for type I interferon responses in

contributing to innate immune protection against mycobacterial disease.

Previous studies report peripheral blood interferon-inducible gene expression that diminishes with

successful treatment in human active TB [7,34,35]. These transcriptional signatures comprise both type

I and type II interferon inducible genes but have mainly been interpreted as type I interferon

responses, fostering the view that type I interferons are detrimental to the host in human TB. In the

present study we found no relationship between disease severity and peripheral blood expression

of gene modules specific for type I interferon activity. Mouse data predominantly suggest that type I

interferon responses contribute to increased susceptibility to mycobacterial infection, by

mechanisms including antagonism of IL1 mediated protection [36–38] and reduced responsiveness of

macrophages to interferon gamma [39]. However, this phenotype has not been universally observed,

likely due to differences in host and pathogen genetics [5]. Moreover, impaired type I interferon

responses are generally associated with relatively minor differences in bacterial burden or survival

[5]. Of note, Mtb is not a natural mouse pathogen, and this approach may not model host-pathogen

interactions in human TB faithfully [6].

In support of a protective role for type I interferons, adjunctive interferon alpha therapy in addition to

conventional anti-tuberculous antibiotic treatment led to symptomatic and radiological improvement,

with a reduction in bacterial burden in respiratory tract samples, in small-scale human studies [40–42].

In keeping with this, an early peripheral blood type I interferon-inducible gene signature predicts

successful BCG-induced protection of macaques from subsequent Mtb challenge [43]. Type I

interferon mediated restriction of mycobacterial growth in in vitro granulomas comprising collagen

impregnated microspheres containing Mtb infected human peripheral blood mononuclear cells

(PBMC) [44] also suggests that type I interferon responses benefit the host.

Our observation of reduced recruitment of macrophages to the site of disease is likely the most

important factor driving increased susceptibility to *M. marinum* infection in *stat2* CRISPants.

Although macrophages have been implicated in the dissemination of *M. marinum* in zebrafish larvae

[23,45], reduction of total macrophage numbers, impaired macrophage migration to the site of

mycobacterial infection or failure to control intracellular bacterial growth within macrophages have

all been associated with poor outcome [23–25,46,47]. In contrast, increasing macrophage numbers via

augmentation of M-CSF signalling either pre- or post-granuloma formation, promotes resistance to

M. marinum infection by reducing granuloma necrosis, with consequent curtailment of extracellular

mycobacterial growth [24]. The recent report that human genetically inherited CCR2 deficiency is

associated with reduced pulmonary recruitment of monocytes, resulting in depleted numbers of

functionally normal alveolar macrophages and increased susceptibility to mycobacteria, is also

consistent with the concept that adequate numbers of macrophages at the site of infection are

important for protective anti-mycobacterial immunity [48].

The reduction in neutrophils present at the site of *M. marinum* infection in *stat2* CRISPants may have

arisen due to baseline neutropenia, defective migration or both combined. On the basis that steady

state neutropenia did not affect the timing and magnitude of peak neutrophil recruitment to sterile

injury, impaired migration is probably the main driver of this phenotype, which likely also contributed

to increased severity of mycobacterial disease. Previous data show that reduced access of

neutrophils to mycobacteria leads to increased bacterial burden in a zebrafish line in which

neutrophils express mutant *cxcr4*, resulting in peripheral neutropenia and impaired neutrophil

recruitment to sites of inflammation, due to their retention in haematopoietic tissue [26,49].

Our study has some limitations. We were not able to address the reasons for variation in type I

interferon activity in our human cohort. Variation in type I interferon responses may arise due to

genetically or epigenetically encoded variation in the immune response to Mtb, neutralising type I

interferon auto-antibodies, burden and virulence of the mycobacterial inoculum and stochasticity in

the immune response pathway following exposure [50–54]. Our sample size is insufficient for robust

detection of associations between genetic variation and the expression levels of type I interferon

signalling pathway genes. Serum samples for measurement of autoantibodies to type I interferons

are not available, although anti-interferon antibodies are very rare in cohorts of this age

distribution [55]. We were also unable to completely disentangle whether reduced neutrophil

recruitment to the site of *M. marinum* infection was a consequence of neutropenia or impaired

migration. We have not determined the mechanism by which attenuated type I interferon signalling

leads to reduced myeloid cell recruitment to *M. marinum*. The expression of several chemokines is

type I interferon inducible [31,56,57] and the CCR2-CCL2 and CXCR3-CXCL11 chemokine axes are

known to be involved in macrophage recruitment to *M. marinum* [45,58]. Future studies are required to

test the hypothesis that *stat2* mutagenesis disrupts chemokine-mediated cellular recruitment to the

site of mycobacterial disease. Nonetheless, our work provides new insights into type I interferon

mediated host protection against mycobacterial infection.

Our findings have potential implications for risk stratification of individuals in whom any of the above

mechanisms predisposing to low type I interferon activity are identified. In active TB, such individuals

could be targeted for longer or more intensive drug regimens, or adjunctive type I interferon therapy

delivered to the respiratory tract, to mitigate against severe disease. Early intervention with type I

interferon treatment, before destruction of the lung parenchyma, is likely to be crucial to augment

macrophage containment of Mtb, but timing and duration of therapy will require evaluation in

relatively large-scale experimental medicine trials.

METHODS

Ethics statement

The study was approved by the London Bloomsbury Research Ethics Committee (16/LO/0776).

Written informed consent was obtained from all participants.

Study design

We aimed to identify human immune pathways that correlate with severity of TB disease, using

transcriptional profiling of biopsies from the TST as a surrogate for immune responses to Mtb in the

lung, and peripheral blood samples. We tested causation for observed associations by genetic

manipulation of identified pathways in the zebrafish larval mycobacterial infection model. To

encompass a broad spectrum of disease severity we recruited 51 adults (>18 years) from four

London hospitals, newly diagnosed with smear or culture positive pulmonary TB, who were within

four weeks of starting treatment. This is in keeping with the median sample size of previous studies

which have successfully demonstrated a relationship between severity of TB disease and

immunological parameters [7,59–62]. Individuals with coincident human immunodeficiency virus

infection, malignancy, taking immunomodulatory therapy, a history of immunization within the

preceding two weeks or previous keloid formation, or unable to give informed consent were

excluded. Study participants underwent blood collection into Tempus tubes before intradermal

injection of 0.1 ml of two units of tuberculin (AJ Vaccines) or saline in the volar aspect of the forearm

as previously described [8–10]. At 48 hours clinical induration at the injection site was measured,

immediately prior to sampling by 3mm punch biopsy as previously described [8,9]. Additional saline

samples from individuals with cured or latent TB, BCG vaccine recipients and healthy volunteers

have been described previously [10]. Control blood samples from healthy individuals have been

described previously [13].

RNA purification from blood, skin biopsy and zebrafish embryo samples

Total blood RNA was extracted using the Tempus Spin RNA Isolation Kit (Ambion; Life

Technologies). Globin mRNA was removed using the GlobinClear kit (Life Technologies). Skin

biopsies were homogenized as previously described [10]. Pooled zebrafish embryos (25-30 per

experimental condition) collected in Qiazol (Qiagen) were homogenized in CK14 lysing kit tubes

(Bertin Instruments) using a Precellys Evolution homogenizer (Bertin Instruments) for 10-20 seconds

at 5500 rpm. Total RNA from skin biopsies and zebrafish samples was purified using the RNEasy

mini and micro kits (Qiagen), respectively, according to the manufacturer's instructions. Genomic

DNA was removed using the TURBO DNA-free kit (ThermoFisher).

Transcriptional profiling of blood, skin biopsy and zebrafish larval samples

Genome-wide mRNA sequencing was performed as previously described [10,63]. Complementary DNA

(cDNA) libraries were prepared using the KAPA HyperPrep kit (Roche). Sequencing was performed

in paired-end mode with the NextSeq 500 High Output 75 Cycle Kit (Illumina) using the NextSeq500

system (Illumina) according to the manufacturer's instructions, generating a median of 24 million

(range 14.7-32.4 million) 41 base pair reads per human blood sample, 22 million (range 12.3-27.9

million) reads per human TST sample and 16.8 million (range 15.1-18.1 million) reads per zebrafish

sample. Transcript alignment and quantitation against the Ensembl GRCh38 human genome

assembly release 100 or GRCz11 zebrafish genome assembly release 104 was performed using

Kallisto [64]. Transcript-level output counts and transcripts per million (TPM) values were summed on

gene level and annotated with Ensembl gene ID, gene name, and gene biotype using the

R/Bioconductor packages tximport and BiomaRt [65,66]. Downstream analysis was performed using R

3.6.3 on log2 transformed TPM values for protein-coding genes only. 0.001 was added to all TPM

values prior to log2 transformation. To determine the need for and effect of batch correction in the

human data, principal component analysis (PCA) was performed using the prcomp R function on the

integrated list of genes with the 10% lowest variance in expression for each library preparation date.

This revealed separation of three TST samples in PC1, likely accounted for by lower RNA

concentrations or RIN values compared to the rest of the dataset (Figure S1A). After batch correction

performed using the ComBat function of the sva R package [67], allocating samples with PC1 score

<0 and >0 to separate batches, this was no longer evident (Figure S1B).

Radiographic quantitation of TB severity

Disease severity was evaluated by estimating the extent of radiographic abnormalities and whether

cavitation was present on chest x-ray at the time of diagnosis, as previously described [10,11].

Outlier analysis

The BioBase Bioconductor R package was used to perform outlier analysis based on the z-score

outlier detection (ZODET) algorithm [12], to identify transcripts in each TB patient blood sample whose

expression was significantly higher than the mean expression in control blood samples from healthy

volunteers [13] and transcripts in each TST sample whose expression was significantly higher than the

mean expression in control saline samples (>2SD, p value <0.05), with a fold difference filter of >1

log2. Chi-squared tests implemented in R were then used to identify outlier genes statistically

enriched in blood samples from TB patients compared to healthy individuals and TST samples

14

compared to saline samples, using a p value <0.05. To avoid type 2 error no correction for multiple

testing was used in this analysis. In instances where multiple Ensembl gene IDs were associated

with a single gene symbol, duplicate gene symbols were removed to retain the replicate with the

highest expression for each sample.

Pathway enrichment analysis

The biological pathways represented by the entire blood and TST transcriptomes and genes in each

transcriptome positively and negatively correlated with radiographic severity score (Spearman rank

correlation p value <0.05, without correction for multiple testing, to prevent type 2 error) were

identified by Reactome pathway enrichment analysis using XGR as previously described [68,69]. For

visualization, 15 pathway groups were identified by hierarchical clustering of Jaccard indices to

quantify similarity between the gene compositions of each pathway. For each group the pathway

term with the largest number of annotated genes was then selected as representative of enriched

biology.

Upstream regulator analysis

Peripheral blood and TST transcriptome genes whose expression was significantly correlated with

radiographic severity of TB disease were identified by Spearman rank correlation, p value <0.05,

without correction for multiple testing, to prevent type 2 error. Genes positively and negatively

correlated with disease severity were separately subjected to Ingenuity Pathway Analysis (Qiagen)

to identify upstream molecules responsible for their transcriptional regulation. This analysis was

restricted to molecules annotated with the following functions: cytokine, transmembrane receptor,

kinase and transcriptional regulator, representing the canonical components of pathways which

mediate transcriptional reprogramming in immune responses. Enriched molecules with an adjusted

p value <0.05 were considered statistically significant.

Upstream regulator functional modules

Blood and TST gene modules representing the functional activity of their upstream molecule were

identified as previously described [13]. In brief, we calculated the average correlation coefficient for

pairwise correlations of the expression levels of the target genes associated with each predicted

upstream regulator. We compared these to the distribution of average correlation coefficients

obtained from 100 iterations of randomly selecting equivalent sized groups of genes from the blood

or TST transcriptome. Only target gene modules with average correlation coefficients higher than

the mean of the distribution of equivalent sized randomly selected groups by ≥2 SD (Z score ≥2) with

false discovery rate <0.05, were retained. We visualised these upstream regulator modules as

network diagrams using the Force Atlas two algorithm in Gephi v0.9.2 [70], depicting all statistically

over-represented molecules (false discovery rate <0.05) predicted to be upstream of ≥4 target genes.

Transcriptional modules

Interferon inducible transcriptional module gene lists are provided in Table S1. Independently derived

human type I and type II interferon inducible gene modules were described previously [9,10,13]. Two

further modules were derived to distinguish type I or type II interferon inducible gene expression

using published transcriptional data for primary human keratinocytes stimulated with a selection of

cytokines (Gene Expression Omnibus accession: GSE36287) [71]. Stimulus-specific modules for type

I interferon (interferon alpha) and type II interferon (interferon gamma) were derived by selecting

genes overexpressed >4-fold in the cognate cytokine condition relative to all non-cognate conditions

combined (paired t test with α of p<0.05 without multiple testing correction), excluding genes also

induced by each non-cognate cytokine condition, using the same criteria. The babelgene R package

(https://igordot.github.io/babelgene/) was used to convert human gene symbols to their respective

zebrafish orthologues to generate the zebrafish Stat1 module, excluding zebrafish genes reported

to be an orthologue of more than one human gene. The zebrafish type I interferon inducible gene

module comprises 360 genes whose expression was significantly induced (≥2 fold, adjusted p value

<0.05) six hours after intravenous injection of three day post-fertilisation (dpf) larvae with 1 nl of

recombinant interferon phi 1 protein (1 mg/ml) as previously described [18].

Venn diagrams

Area-proportional Venn diagrams visualizing the overlap between constituent genes in

transcriptional modules were generated using BioVenn [72].

Zebrafish husbandry

Zebrafish were raised and maintained at 28.5°C following a 14/10 light/dark cycle according to standard protocols [73] in University College London (UCL) and Neuro-PSI Zebrafish Facilities. All work was approved by the British Home Office (Project License PP8780756) and the French Ministry for Research and Higher Education (Project License 39238). All experiments were performed in accordance with the relevant guidelines and regulations, on larvae up to five days post-fertilisation, before they are protected under the Animals (Scientific Procedures) Act. Adult zebrafish were spawned to collect embryos for experiments. Table S2 lists the lines used in this study [22,28,29]. Embryos were maintained at 28.5°C in egg water containing 60 µg/ml Tropic Marin Sea Salt (Norwood Aquarium) and anaesthetised with egg water containing 200 µg/ml buffered tricaine (3-aminobenzoic acid ethyl ester) (Sigma-Aldrich) during injection, tail fin transection and imaging. Larvae used for in vivo imaging were maintained in egg water supplemented at 24 hours post-fertilisation (hpf) with 0.003% PTU (1-phenyl-2-thiourea) (Sigma-Aldrich) to inhibit melanisation.

CRISPant Generation

To maximise the likelihood of loss of functional protein we employed a previously described triple-exon targeting approach [74], with the modification that Cas9 protein was not diluted before use. CRISPR RNA (crRNA) (Alt-R CRISPR-Cas9 crRNA), tracrRNA (Alt-R CRISPR-Cas9 tracrRNA) and recombinant Cas9 protein (Alt-R Streptococcus pyogenes Cas9 Nuclease V3) were obtained from Integrated DNA Technologies (IDT). Three pre-designed crRNAs targeting distinct exons were selected for the *stat2* gene, prioritizing those that targeted early, asymmetric (not divisible by three) exons common to both protein-coding transcripts, with low off-target and high on-target scores and in a genomic position which allowed design of primers flanking the target site to generate a ~200 bp amplicon, for verification of mutagenesis by next generation sequencing (MiSeq). crRNA sequences and genomic locations are provided in Table S3. To generate gRNAs equal volumes of crRNA and tracrRNA diluted to 61 µM in Duplex buffer (IDT) were annealed at 95°C for 5 minutes. Equal volumes of gRNA (61 µM) and Cas9 protein (61 µM) were incubated at 37°C for 5 minutes to assemble separate 30.5 µM ribonucleoproteins (RNPs) for each target. Equal volumes of the three RNPs were pooled, prior to injection giving a final concentration of 10.2 µM for each. Negative control

"scrambled" crRNAs computationally designed to be non-targeting (Alt-R CRISPRCas9 Negative

Control crRNA #1, #2, #3) were prepared and pooled as described above. 0.5 nl of pooled *stat2*

RNPs or scrambled RNPs was injected into the yolk sac of single-cell stage wild type or transgenic

zebrafish embryos before cell inflation as previously described [74]. After injections embryos were

transferred into sterile petri dishes with fresh egg water and maintained at 28.5°C to the appropriate

age for experiments, as described below.

Interferon phi 1 stimulation

Three dpf *stat2* CRISPant *Tg(mxa:mCherry)* larvae and scrambled RNP injected siblings were

injected in the coelomic cavity with 1 nl of recombinant zebrafish interferon phi 1 protein (1.25 mg/ml),

produced as previously described [75]. *stat2* and control CRISPants were shuffled so that injections

were performed blindly. Bovine serum albumin (BSA) (1.25 mg/ml) was injected as a control.

Interferon phi 1 and BSA solutions were supplemented with 0.2% phenol red (Sigma-Aldrich) to

visualize the inoculum. Induction of Mxa reporter expression was determined by fluorescence

microscopy 24 hours post-injection.

M. marinum **infection**

M. marinum M strain expressing the pmsp12 mWasabi [76] or psMT3 mCherry plasmid [77] was cultured

using Middlebrook 7H10 agar (Becton Dickinson and Company) supplemented with 0.5% oleic

acid/albumin/dextrose/catalase (OADC) (Becton Dickinson and Company), 0.5% glycerol (Sigma-

Aldrich) and hygromycin (50 µg/ml) (Fisher Scientific). To generate bacterial suspensions for

injection, *M. marinum* from agar plates was cultured statically at 28.5°C for 24-36 hours in 10 ml

Middlebrook 7H9 broth (Becton Dickinson and Company) supplemented with 10%

albumin/dextrose/catalase (ADC) (Becton Dickinson and Company) and hygromycin (50 µg/ml)

(Fisher Scientific). Bacteria were harvested at mid-log growth (optical density (OD)600nm 0.7–1),

(OD)600nm 1 representing 10^8 colony forming units (cfu)/ml, washed three times in phosphate

buffered saline (PBS) (Gibco) and resuspended in 2% polyvinylpyrrolidone (PVP)40 (Sigma-

Aldrich)/PBS containing 10% phenol red (Sigma-Aldrich) to aid visualisation of injections [78].

Zebrafish embryos were manually dechorionated using jeweller's forceps (Dumont #5, World

Precision Instruments) prior to bacterial infection. To generate systemic infection, 400 cfu

M. marinum in a volume of 1 nl were microinjected into the caudal vein of embryos staged at

28-30 hpf. Four days post-infection, embryos were either subjected to fluorescence microscopy to

measure disease severity or 25-30 per condition pooled and harvested in Qiazol (Qiagen) for

evaluation of immune responses by RNAseq. To generate localised infection, 200 cfu *M. marinum*

in a volume of 1 nl were injected into the hindbrain ventricle (HBV) of two dpf zebrafish larvae.

Cellular recruitment was evaluated by fluorescence microscopy at 6-18 hours post-infection.

Tailfin transection

Tailfin transections were performed as described previously [29,79]. Briefly, live anaesthetised three dpf

zebrafish larvae were transferred with a 1 ml Pasteur pipette (Scientific Laboratory Supplies) to a

sterile petri dish containing 2% agarose (Bioline). Transections of the caudal fin were performed

using a sterile microscalpel (World Precision Instruments) by applying steady downward pressure to

create the incision at the boundary with the notochord. Following injury, larvae were rinsed in egg

water and maintained in individual wells of a 96-well tissue culture plate (TPP) at 28.5°C until live

imaging to quantify neutrophil or macrophage recruitment to the site of injury at 1, 6 and 24 hours-

post-wound (hpw).

Fluorescence microscopy

All fluorescence microscopy was performed on live, anasethised larvae. For quantitation of bacterial

burden and dissemination four days post-infection, steady state neutrophil numbers at two dpf and

cellular recruitment at 2-4 dpf, larvae were imaged using an M205FA stereofluorescence microscope

(Leica) with a 1x objective. Larvae were imaged on a flat 1% agarose plate for quantitation of severity

of mycobacterial infection and steady state neutrophil numbers and a 96-well tissue culture plate

(TPP) in which the wells were coated with 1% agarose, for cellular recruitment to tailfin transection.

Micro-wells were created in 1% agarose using a Stampwell Larvae 1 device (Idylle) for optimal

positioning of 2-3 dpf larvae for imaging of cellular recruitment to hindbrain ventricle *M. marinum*

infection. Brightfield and fluorescence images were captured using a DFC365 FX camera (Leica)

and exported as 16-bit Tagged Image Format (TIF) files for analysis. For quantitation of steady state

macrophage numbers three dpf larvae were imaged in 96-well alignment plates (Funakoshi)

containing 75 µl egg water per well using a high-content wide-field fluorescence microscope

(Hermes, IDEA Bio-Medical) with a 4x objective, capturing five z planes 50.6 µm apart in four

contiguous fields of view per embryo. We created an ImageJ macro to semi-automate generation of

single maximum intensity projection z-stack montages from the Hermes images, which were saved

as 16-bit TIF files for analysis (Table S4). Mxa reporter expression was recorded with an EVOS

M7000 microscope (ThermoFisher) equipped with a 2x/NA0.06 objective and Texas Red

fluorescence cube. Larvae were positioned laterally in micro-wells created in 2% agarose with an in-

house-printed stamp. A single fluorescence plane was recorded as the depth of field is sufficient to

capture the entire larva. Transmitted light images were also recorded and both were exported as 16-

bit TIF files.

Image analysis

To quantify bacterial burden, number of bacterial foci and spatial distribution of bacteria, images

were analysed using custom QuantiFish software, previously developed in our group, to enable rapid

quantitation of fluorescent foci in zebrafish larvae [80]. Mxa reporter fluorescence was measured with

ImageJ. Transmitted and fluorescence images were stacked. Images were slightly rotated to

horizontality where necessary. A 600x100 pixel rectangular region of interest was defined on the

transmitted light image to encompass the entire gut and liver areas. Mean fluorescence intensity was

then measured on the fluorescence image. For quantitation of total cell number and recruitment of

fluorescent immune cells to the site of tailfin transection we developed a new custom Python script

which enables quantitation of integrated fluorescence within concentric zones (known as Sholl

circles) [81] (Figure S9). To achieve this, the script leverages the OpenCV, NumPy [82], Matplotlib, SciPy

(http://www.scipy.org), scikit-image [83] and pandas Python libraries to facilitate image processing and

data extraction (Table S5). First the user is prompted to select a folder containing images for

analysis, as well as the file extensions corresponding to the brightfield and fluorescence images,

which are essential for the subsequent steps. The script then iterates through each pair of brightfield

and fluorescent images prompting the user to define two points on the brightfield image, which serve

as the start and end positions between which to create concentric circular regions [81] on the

corresponding fluorescence image. The script employs the image processing techniques described

in Table S5 to quantify integrated fluorescence of the entire image and that within each region, as

surrogates for the total number of immune cells and the number at each spatial location, respectively

and generates output files containing this information. Integrated fluorescence within the first zone

(the wound site) and distance from the site of tailfin transection of the zone in which the maximal

integrated fluorescence (a surrogate for the highest cell numbers) was detected (identified manually)

were used as measures of immune cell recruitment for each zebrafish larva. The number of cells

recruited to the site of hindbrain *M. marinum* infection was quantified by manual counting.

Genotyping by next generation sequencing

Genomic DNA extraction

Genomic DNA was extracted from anasethetised individual zebrafish larvae using the modified hot

sodium hydroxide and Tris (HotSHOT) method as previously described [74,84]. Briefly, larvae in 96-well

plates were incubated in 50 μl base solution (25 mM KOH, 0.2 mM EDTA in water) at 95°C for 30

min then cooled to room temperature, before addition of 50 μl neutralization solution (40 mM Tris-

HCL in water).

PCR

Extracted DNA (2 μl per 50 μl reaction) was subjected to PCR using Phusion High-Fidelity DNA

Polymerase (New England Biolabs) (98°C for 30 seconds (s), once only, 40 cycles of 98°C for 10 s,

59°C for 30 s, 72°C for 20 s, 72°C for 10 minutes, once only). Sequences and genomic positions of

the primers used are provided in Table S3. Successful amplification of a single product of

approximately 300 bp was verified by 2% agarose (Bioline) Tris-borate-EDTA (TBE) containing

Redsafe (Chembio) gel electrophoresis. PCR products were purified using ExoSAP-IT Express

(ThermoFisher), concentration of purified DNA determined by Nanodrop spectrophotometer

(ThermoFisher) and samples diluted to 15-25 ng/μl for sequencing.

Next generation sequencing and data analysis

Sequencing was performed by the UCL Fish Genomic Service using the MiSeq Reagent Kit v2 (300-

cycles) (Illumina) and the MiSeq system (Illumina) in paired end mode, according to the

manufacturer's instructions. Sequencing data were received as two FASTQ files (forward and

reverse) for each sample. Visual sequence analysis was performed using Geneious 10.2.6

(https://www.geneious.com) for initial verification of successful genome editing close to the PAM site.

Objective quantitation of the proportion of reads mutated and predicted to be frameshifted was

achieved using the ampliCan R package [85], which utilizes the FASTQ files and a metadata file

providing the amplicon, protospacer adjacent motif (PAM) and primer sequences (Table S3) and

sample information, as previously described [74]. AmpliCan was run with default parameters, with the

exception that min_freq = 0.005 (mutations at a frequency below this threshold were considered a

sequencing error) and average_quality = 25. Mutations present in uninjected or scrambled RNP

injected control samples were not included as Cas9 induced mutations.

Statistical analysis

Statistical analysis was performed using GraphPad Prism 9.3.1 for Windows (GraphPad Software)

and R3.6.3. Chi-squared tests were used to identify outlier genes statistically enriched in

transcriptomic data from blood samples from people with TB compared to healthy individuals and

TST samples compared to saline samples, with no correction for multiple testing to avoid type 2

error. Spearman rank correlation was used to determine the strength of relationship between blood

and TST transcriptome gene expression and TB disease severity (two-tailed), transcript levels of

upstream regulator target gene modules, blood and TST random gene modules (one-tailed, positive

correlation only) and mean expression of transcriptional modules in blood and TST transcriptomic

data with severity of TB disease (two-tailed). The Benjamini-Hochberg correction method for multiple

comparisons was used to identify upstream regulator target gene modules with average correlation

coefficients significantly higher than the mean of the distribution of equivalent sized randomly

selected gene modules by ≥2 SD (Z score ≥2) with false discovery rate <0.05. Survival of *stat2*

CRISPant and control zebrafish larvae was compared using a log-rank (Mantel-Cox) test; a p value

<0.05 was considered significant. On scatter plots horizontal lines represent median values and error

bars indicate the interquartile range. On box and whisker plots horizontal lines represent median

values, box limits indicate the interquartile range and whiskers extend between the 5th and 95th

percentiles of the data. Two-tailed Mann-Whitney tests were used for two group comparisons of

unpaired data; a p value <0.05 was considered significant. Where p values are not presented on

graphs, * denotes p<0.05.

REFERENCES

1.   Coussens, A.K., Zaidi, S.M.A., Allwood, B.W., Dewan, P.K., Gray, G., Kohli, M., Kredo, T.,
Marais, B.J., Marks, G.B., Martinez, L., et al. (2024). Classification of early tuberculosis states
to guide research for improved care and prevention: an international Delphi consensus exercise.
Lancet Respir. Med. *12*, 484–498. https://doi.org/10.1016/S2213-2600(24)00028-6.

2.   Cadena, A.M., Fortune, S.M., and Flynn, J.L. (2017). Heterogeneity in tuberculosis. Nat. Rev.
Immunol. *17*, 691–702. https://doi.org/10.1038/nri.2017.69.

3.   Kaufmann, S.H.E., Lange, C., Rao, M., Balaji, K.N., Lotze, M., Schito, M., Zumla, A.I., and
Maeurer, M. (2014). Progress in tuberculosis vaccine development and host-directed therapies-
-a state of the art review. Lancet Respir. Med. *2*, 301–320. https://doi.org/10.1016/S2213-
2600(14)70033-5.

4.   Kinsella, R.L., Zhu, D.X., Harrison, G.A., Mayer Bridwell, A.E., Prusa, J., Chavez, S.M., and
Stallings, C.L. (2021). Perspectives and Advances in the Understanding of Tuberculosis. Annu.
Rev. Pathol. Mech. Dis. *16*, 377–408. https://doi.org/10.1146/annurev-pathol-042120-032916.

5.   Moreira-Teixeira, L., Mayer-Barber, K., Sher, A., and O'Garra, A. (2018). Type I interferons in
tuberculosis: Foe and occasionally friend. J. Exp. Med. *215*, 1273–1285.
https://doi.org/10.1084/jem.20180325.

6.   Kramnik, I., and Beamer, G. (2016). Mouse models of human TB pathology: roles in the analysis
of necrosis and the development of host-directed therapies. Semin. Immunopathol. *38*, 221–237.
https://doi.org/10.1007/s00281-015-0538-9.

7.   Berry, M.P.R., Graham, C.M., McNab, F.W., Xu, Z., Bloch, S.A.A., Oni, T., Wilkinson, K.A.,
Banchereau, R., Skinner, J., Wilkinson, R.J., et al. (2010). An interferon-inducible neutrophil-
driven blood transcriptional signature in human tuberculosis. Nature *466*, 973–977.
https://doi.org/10.1038/nature09247.

8.   Tomlinson, G.S., Cashmore, T.J., Elkington, P.T.G., Yates, J., Lehloenya, R.J., Tsang, J.,
Brown, M., Miller, R.F., Dheda, K., Katz, D.R., et al. (2011). Transcriptional profiling of innate
and adaptive human immune responses to mycobacteria in the tuberculin skin test. Eur. J.
Immunol. *41*, 3253–3260. https://doi.org/10.1002/eji.201141841.

9.   Bell, L.C.K., Pollara, G., Pascoe, M., Tomlinson, G.S., Lehloenya, R.J., Roe, J., Meldau, R.,
Miller, R.F., Ramsay, A., Chain, B.M., et al. (2016). In Vivo Molecular Dissection of the Effects
of HIV-1 in Active Tuberculosis. PLoS Pathog. *12*, e1005469.
https://doi.org/10.1371/journal.ppat.1005469.

10. Pollara, G., Turner, C.T., Rosenheim, J., Chandran, A., Bell, L.C.K., Khan, A., Patel, A., Peralta,
L.F., Folino, A., Akarca, A., et al. (2021). Exaggerated IL-17A activity in human in vivo recall
responses discriminates active tuberculosis from latent infection and cured disease. Sci. Transl.
Med. *13*, eabg7673. https://doi.org/10.1126/scitranslmed.abg7673.

11. Ralph, A.P., Ardian, M., Wiguna, A., Maguire, G.P., Becker, N.G., Drogumuller, G., Wilks, M.J.,
Waramori, G., Tjitra, E., Sandjaja, null, et al. (2010). A simple, valid, numerical score for grading
chest x-ray severity in adult smear-positive pulmonary tuberculosis. Thorax *65*, 863–869.
https://doi.org/10.1136/thx.2010.136242.

12. Roden, D.L., Sewell, G.W., Lobley, A., Levine, A.P., Smith, A.M., and Segal, A.W. (2014).
ZODET: software for the identification, analysis and visualisation of outlier genes in microarray
expression data. PloS One *9*, e81123. https://doi.org/10.1371/journal.pone.0081123.

13. Chandran, A., Rosenheim, J., Nageswaran, G., Swadling, L., Pollara, G., Gupta, R.K., Burton,
A.R., Guerra-Assunção, J.A., Woolston, A., Ronel, T., et al. (2022). Rapid synchronous type 1
IFN and virus-specific T cell responses characterize first wave non-severe SARS-CoV-2
infections. Cell Rep. Med. *3*, 100557. https://doi.org/10.1016/j.xcrm.2022.100557.

14. Paduano, F., Gaudio, E., Mensah, A.A., Pinton, S., Bertoni, F., and Trapasso, F. (2018). T-Cell
Leukemia/Lymphoma 1 (TCL1): An Oncogene Regulating Multiple Signaling Pathways. Front.
Oncol. *8*, 317. https://doi.org/10.3389/fonc.2018.00317.

15. McNab, F., Mayer-Barber, K., Sher, A., Wack, A., and O'Garra, A. (2015). Type I interferons in
infectious disease. Nat. Rev. Immunol. *15*, 87–103. https://doi.org/10.1038/nri3787.

16. Ramakrishnan, L. (2013). The zebrafish guide to tuberculosis immunity and treatment. Cold
Spring Harb. Symp. Quant. Biol. *78*, 179–192. https://doi.org/10.1101/sqb.2013.78.023283.

17. Langevin, C., Aleksejeva, E., Passoni, G., Palha, N., Levraud, J.-P., and Boudinot, P. (2013).
The antiviral innate immune response in fish: evolution and conservation of the IFN system. J.
Mol. Biol. *425*, 4904–4920. https://doi.org/10.1016/j.jmb.2013.09.033.

18. Levraud, J.-P., Jouneau, L., Briolat, V., Laghi, V., and Boudinot, P. (2019). IFN-Stimulated
Genes in Zebrafish and Humans Define an Ancient Arsenal of Antiviral Immunity. J. Immunol.
Baltim. Md 1950 *203*, 3361–3373. https://doi.org/10.4049/jimmunol.1900804.

19. Blaszczyk, K., Nowicka, H., Kostyrko, K., Antonczyk, A., Wesoly, J., and Bluyssen, H.A.R.
(2016). The unique role of STAT2 in constitutive and IFN-induced transcription and antiviral
responses. Cytokine Growth Factor Rev. *29*, 71–81.
https://doi.org/10.1016/j.cytogfr.2016.02.010.

20. Begitt, A., Droescher, M., Meyer, T., Schmid, C.D., Baker, M., Antunes, F., Knobeloch, K.-P.,
Owen, M.R., Naumann, R., Decker, T., et al. (2014). STAT1-cooperative DNA binding
distinguishes type 1 from type 2 interferon signaling. Nat. Immunol. *15*, 168–176.
https://doi.org/10.1038/ni.2794.

21. Schoggins, J.W. (2019). Interferon-Stimulated Genes: What Do They All Do? Annu. Rev. Virol.
6, 567–584. https://doi.org/10.1146/annurev-virology-092818-015756.

22. Maarifi, G., Smith, N., Maillet, S., Moncorgé, O., Chamontin, C., Edouard, J., Sohm, F., Blanchet,
F.P., Herbeuval, J.-P., Lutfalla, G., et al. (2019). TRIM8 is required for virus-induced IFN
response in human plasmacytoid dendritic cells. Sci. Adv. *5*, eaax3511.
https://doi.org/10.1126/sciadv.aax3511.

23. Clay, H., Davis, J.M., Beery, D., Huttenlocher, A., Lyons, S.E., and Ramakrishnan, L. (2007).
Dichotomous role of the macrophage in early Mycobacterium marinum infection of the zebrafish.
Cell Host Microbe *2*, 29–39. https://doi.org/10.1016/j.chom.2007.06.004.

24. Pagán, A.J., Yang, C.-T., Cameron, J., Swaim, L.E., Ellett, F., Lieschke, G.J., and
Ramakrishnan, L. (2015). Myeloid Growth Factors Promote Resistance to Mycobacterial
Infection by Curtailing Granuloma Necrosis through Macrophage Replenishment. Cell Host
Microbe *18*, 15–26. https://doi.org/10.1016/j.chom.2015.06.008.

25. Berg, R.D., Levitte, S., O'Sullivan, M.P., O'Leary, S.M., Cambier, C.J., Cameron, J., Takaki, K.K.,
Moens, C.B., Tobin, D.M., Keane, J., et al. (2016). Lysosomal Disorders Drive Susceptibility to
Tuberculosis by Compromising Macrophage Migration. Cell *165*, 139–152.

https://doi.org/10.1016/j.cell.2016.02.034.

26. Yang, C.-T., Cambier, C.J., Davis, J.M., Hall, C.J., Crosier, P.S., and Ramakrishnan, L. (2012).
Neutrophils exert protection in the early tuberculous granuloma by oxidative killing of
mycobacteria phagocytosed from infected macrophages. Cell Host Microbe *12*, 301–312.
https://doi.org/10.1016/j.chom.2012.07.009.

27. Elks, P.M., Brizee, S., van der Vaart, M., Walmsley, S.R., van Eeden, F.J., Renshaw, S.A., and
Meijer, A.H. (2013). Hypoxia inducible factor signaling modulates susceptibility to mycobacterial
infection via a nitric oxide dependent mechanism. PLoS Pathog. *9*, e1003789.
https://doi.org/10.1371/journal.ppat.1003789.

28. Voelz, K., Gratacap, R.L., and Wheeler, R.T. (2015). A zebrafish larval model reveals early
tissue-specific innate immune responses to Mucor circinelloides. Dis. Model. Mech. *8*, 1375–
1388. https://doi.org/10.1242/dmm.019992.

29. Renshaw, S.A., Loynes, C.A., Trushell, D.M.I., Elworthy, S., Ingham, P.W., and Whyte, M.K.B.
(2006). A transgenic zebrafish model of neutrophilic inflammation. Blood *108*, 3976–3978.
https://doi.org/10.1182/blood-2006-05-024075.

30. Bucciol, G., Moens, L., Ogishi, M., Rinchai, D., Matuozzo, D., Momenilandi, M., Kerrouche, N.,
Cale, C.M., Treffeisen, E.R., Al Salamah, M., et al. (2023). Human inherited complete STAT2
deficiency underlies inflammatory viral diseases. J. Clin. Invest. *133*, e168321.
https://doi.org/10.1172/JCI168321.

31. Rauch, I., Müller, M., and Decker, T. (2013). The regulation of inflammation by interferons and
their STATs. JAK-STAT *2*, e23820. https://doi.org/10.4161/jkst.23820.

32. Gray, C., Loynes, C.A., Whyte, M.K.B., Crossman, D.C., Renshaw, S.A., and Chico, T.J.A.
(2011). Simultaneous intravital imaging of macrophage and neutrophil behaviour during
inflammation using a novel transgenic zebrafish. Thromb. Haemost. *105*, 811–819.
https://doi.org/10.1160/TH10-08-0525.

33. Ellett, F., Pase, L., Hayman, J.W., Andrianopoulos, A., and Lieschke, G.J. (2011). mpeg1
promoter transgenes direct macrophage-lineage expression in zebrafish. Blood *117*, e49-56.
https://doi.org/10.1182/blood-2010-10-314120.

34. Bloom, C.I., Graham, C.M., Berry, M.P.R., Wilkinson, K.A., Oni, T., Rozakeas, F., Xu, Z.,
Rossello-Urgell, J., Chaussabel, D., Banchereau, J., et al. (2012). Detectable Changes in The
Blood Transcriptome Are Present after Two Weeks of Antituberculosis Therapy. PLOS ONE *7*,
e46191. https://doi.org/10.1371/journal.pone.0046191.

35. Ottenhoff, T.H.M., Dass, R.H., Yang, N., Zhang, M.M., Wong, H.E.E., Sahiratmadja, E., Khor,
C.C., Alisjahbana, B., Crevel, R. van, Marzuki, S., et al. (2012). Genome-Wide Expression
Profiling Identifies Type 1 Interferon Response Pathways in Active Tuberculosis. PLOS ONE *7*,
e45839. https://doi.org/10.1371/journal.pone.0045839.

36. Mayer-Barber, K.D., Andrade, B.B., Barber, D.L., Hieny, S., Feng, C.G., Caspar, P., Oland, S.,
Gordon, S., and Sher, A. (2011). Innate and Adaptive Interferons Suppress IL-1α and IL-1β
Production by Distinct Pulmonary Myeloid Subsets during Mycobacterium tuberculosis Infection.
Immunity *35*, 1023–1034. https://doi.org/10.1016/j.immuni.2011.12.002.

37. Mayer-Barber, K.D., Andrade, B.B., Oland, S.D., Amaral, E.P., Barber, D.L., Gonzales, J.,
Derrick, S.C., Shi, R., Kumar, N.P., Wei, W., et al. (2014). Host-directed therapy of tuberculosis
based on interleukin-1 and type I interferon crosstalk. Nature *511*, 99–103.
https://doi.org/10.1038/nature13489.

38. Ji, D.X., Yamashiro, L.H., Chen, K.J., Mukaida, N., Kramnik, I., Darwin, K.H., and Vance, R.E. (2019). Type I interferon-driven susceptibility to Mycobacterium tuberculosis is mediated by IL-1Ra. Nat. Microbiol. *4*, 2128–2135. https://doi.org/10.1038/s41564-019-0578-3.

39. Kotov, D.I., Lee, O.V., Fattinger, S.A., Langner, C.A., Guillen, J.V., Peters, J.M., Moon, A., Burd, E.M., Witt, K.C., Stetson, D.B., et al. (2023). Early cellular mechanisms of type I interferon-driven susceptibility to tuberculosis. Cell *186*, 5536-5553.e22. https://doi.org/10.1016/j.cell.2023.11.002.

40. Giosué, S., Casarini, M., Alemanno, L., Galluccio, G., Mattia, P., Pedicelli, G., Rebek, L., Bisetti, A., and Ameglio, F. (1998). Effects of aerosolized interferon-alpha in patients with pulmonary tuberculosis. Am. J. Respir. Crit. Care Med. *158*, 1156–1162. https://doi.org/10.1164/ajrccm.158.4.9803065.

41. Zarogoulidis, P., Kioumis, I., Papanas, N., Manika, K., Kontakiotis, T., Papagianis, A., and Zarogoulidis, K. (2012). The effect of combination IFN-alpha-2a with usual antituberculosis chemotherapy in non-responding tuberculosis and diabetes mellitus: a case report and review of the literature. J. Chemother. *24*, 173–177. https://doi.org/10.1179/1973947812Y.0000000005.

42. Mansoori, D., Tavana, S., Mirsaeidi, M., Yazdanpanah, M., and Sohrabpour, H. (2002). The Efficacy of Interferon-α in the Treatment of Multidrug Resistant Tuberculosis. TANAFFOS *1*, 29–34.

43. Liu, Y.E., Darrah, P.A., Zeppa, J.J., Kamath, M., Laboune, F., Douek, D.C., Maiello, P., Roederer, M., Flynn, J.L., Seder, R.A., et al. (2023). Blood transcriptional correlates of BCG-induced protection against tuberculosis in rhesus macaques. Cell Rep. Med. *4*, 101096. https://doi.org/10.1016/j.xcrm.2023.101096.

44. Tezera, L.B., Bielecka, M.K., Chancellor, A., Reichmann, M.T., Shammari, B.A., Brace, P., Batty, A., Tocheva, A., Jogai, S., Marshall, B.G., et al. (2017). Dissection of the host-pathogen interaction in human tuberculosis using a bioengineered 3-dimensional model. eLife *6*, e21283. https://doi.org/10.7554/eLife.21283.

45. Torraca, V., Cui, C., Boland, R., Bebelman, J.-P., van der Sar, A.M., Smit, M.J., Siderius, M., Spaink, H.P., and Meijer, A.H. (2015). The CXCR3-CXCL11 signaling axis mediates macrophage recruitment and dissemination of mycobacterial infection. Dis. Model. Mech. *8*, 253–269. https://doi.org/10.1242/dmm.017756.

46. Davis, J.M., Clay, H., Lewis, J.L., Ghori, N., Herbomel, P., and Ramakrishnan, L. (2002). Real-time visualization of mycobacterium-macrophage interactions leading to initiation of granuloma formation in zebrafish embryos. Immunity *17*, 693–702. https://doi.org/10.1016/s1074-7613(02)00475-2.

47. Tobin, D.M., Roca, F.J., Oh, S.F., McFarland, R., Vickery, T.W., Ray, J.P., Ko, D.C., Zou, Y., Bang, N.D., Chau, T.T.H., et al. (2012). Host genotype-specific therapies can optimize the inflammatory response to mycobacterial infections. Cell *148*, 434–446. https://doi.org/10.1016/j.cell.2011.12.023.

48. Neehus, A.-L., Carey, B., Landekic, M., Panikulam, P., Deutsch, G., Ogishi, M., Arango-Franco, C.A., Philippot, Q., Modaresi, M., Mohammadzadeh, I., et al. (2024). Human inherited CCR2 deficiency underlies progressive polycystic lung disease. Cell *187*, 390-408.e23. https://doi.org/10.1016/j.cell.2023.11.036.

49. Walters, K.B., Green, J.M., Surfus, J.C., Yoo, S.K., and Huttenlocher, A. (2010). Live imaging of neutrophil motility in a zebrafish model of WHIM syndrome. Blood *116*, 2803–2811. https://doi.org/10.1182/blood-2010-03-276972.

50. Abel, L., Fellay, J., Haas, D.W., Schurr, E., Srikrishna, G., Urbanowski, M., Chaturvedi, N., Srinivasan, S., Johnson, D.H., and Bishai, W.R. (2018). Genetics of human susceptibility to active and latent tuberculosis: present knowledge and future perspectives. Lancet Infect. Dis. *18*, e64–e75. https://doi.org/10.1016/S1473-3099(17)30623-0.

51. Khadela, A., Chavda, V.P., Postwala, H., Shah, Y., Mistry, P., and Apostolopoulos, V. (2022). Epigenetics in Tuberculosis: Immunomodulation of Host Immune Response. Vaccines *10*, 1740. https://doi.org/10.3390/vaccines10101740.

52. Jacobs, A.L. (1941). Infective dose in pulmonary tuberculosis. Tubercle *22*, 266–271. https://doi.org/10.1016/S0041-3879(41)80017-8.

53. Plumlee, C.R., Duffy, F.J., Gern, B.H., Delahaye, J.L., Cohen, S.B., Stoltzfus, C.R., Rustad, T.R., Hansen, S.G., Axthelm, M.K., Picker, L.J., et al. (2021). Ultra-low Dose Aerosol Infection of Mice with Mycobacterium tuberculosis More Closely Models Human Tuberculosis. Cell Host Microbe *29*, 68-82.e5. https://doi.org/10.1016/j.chom.2020.10.003.

54. Casanova, J.-L., and Anderson, M.S. Unlocking life-threatening COVID-19 through two types of inborn errors of type I IFNs. J. Clin. Invest. *133*, e166283. https://doi.org/10.1172/JCI166283.

55. Bastard, P., Gervais, A., Le Voyer, T., Rosain, J., Philippot, Q., Manry, J., Michailidis, E., Hoffmann, H.-H., Eto, S., Garcia-Prat, M., et al. (2021). Autoantibodies neutralizing type I IFNs are present in ~4% of uninfected individuals over 70 years old and account for ~20% of COVID-19 deaths. Sci. Immunol. *6*, eabl4340. https://doi.org/10.1126/sciimmunol.abl4340.

56. Lehmann, M.H., Torres-Domínguez, L.E., Price, P.J.R., Brandmüller, C., Kirschning, C.J., and Sutter, G. (2016). CCL2 expression is mediated by type I IFN receptor and recruits NK and T cells to the lung during MVA infection. J. Leukoc. Biol. *99*, 1057–1064. https://doi.org/10.1189/jlb.4MA0815-376RR.

57. Buttmann, M., Merzyn, C., and Rieckmann, P. (2004). Interferon-beta induces transient systemic IP-10/CXCL10 chemokine release in patients with multiple sclerosis. J. Neuroimmunol. *156*, 195–203. https://doi.org/10.1016/j.jneuroim.2004.07.016.

58. Cambier, C.J., Takaki, K.K., Larson, R.P., Hernandez, R.E., Tobin, D.M., Urdahl, K.B., Cosma, C.L., and Ramakrishnan, L. (2014). Mycobacteria manipulate macrophage recruitment through coordinated use of membrane lipids. Nature *505*, 218–222. https://doi.org/10.1038/nature12799.

59. Elkington, P., Shiomi, T., Breen, R., Nuttall, R.K., Ugarte-Gil, C.A., Walker, N.F., Saraiva, L., Pedersen, B., Mauri, F., Lipman, M., et al. (2011). MMP-1 drives immunopathology in human tuberculosis and transgenic mice. J. Clin. Invest. *121*, 1827–1833. https://doi.org/10.1172/JCI45666.

60. Guglielmetti, L., Cazzadori, A., Conti, M., Boccafoglio, F., Vella, A., Ortolani, R., and Concia, E. (2013). Lymphocyte subpopulations in active tuberculosis: association with disease severity and the QFT-GIT assay. Int. J. Tuberc. Lung Dis. Off. J. Int. Union Tuberc. Lung Dis. *17*, 825–828. https://doi.org/10.5588/ijtld.12.0361.

61. Jurado, J.O., Pasquinelli, V., Alvarez, I.B., Peña, D., Rovetta, A.I., Tateosian, N.L., Romeo, H.E., Musella, R.M., Palmero, D., Chuluyán, H.E., et al. (2012). IL-17 and IFN-γ expression in lymphocytes from patients with active tuberculosis correlates with the severity of the disease. J. Leukoc. Biol. *91*, 991–1002. https://doi.org/10.1189/jlb.1211619.

62. Hasan, Z., Jamil, B., Khan, J., Ali, R., Khan, M.A., Nasir, N., Yusuf, M.S., Jamil, S., Irfan, M., and Hussain, R. (2009). Relationship between circulating levels of IFN-gamma, IL-10, CXCL9 and CCL2 in pulmonary and extrapulmonary tuberculosis is dependent on disease severity. Scand. J. Immunol. *69*, 259–267. https://doi.org/10.1111/j.1365-3083.2008.02217.x.

63. Roe, J., Venturini, C., Gupta, R.K., Gurry, C., Chain, B.M., Sun, Y., Southern, J., Jackson, C.,
Lipman, M.C., Miller, R.F., et al. (2020). Blood Transcriptomic Stratification of Short-term Risk in
Contacts of Tuberculosis. Clin. Infect. Dis. Off. Publ. Infect. Dis. Soc. Am. *70*, 731–737.
https://doi.org/10.1093/cid/ciz252.

64. Bray, N.L., Pimentel, H., Melsted, P., and Pachter, L. (2016). Near-optimal probabilistic RNA-
seq quantification. Nat. Biotechnol. *34*, 525–527. https://doi.org/10.1038/nbt.3519.

65. Soneson, C., Love, M.I., and Robinson, M.D. (2015). Differential analyses for RNA-seq:
transcript-level estimates improve gene-level inferences. F1000Research *4*, 1521.
https://doi.org/10.12688/f1000research.7563.2.

66. Durinck, S., Spellman, P.T., Birney, E., and Huber, W. (2009). Mapping identifiers for the
integration of genomic datasets with the R/Bioconductor package biomaRt. Nat. Protoc. *4*, 1184–
1191. https://doi.org/10.1038/nprot.2009.97.

67. Leek, J.T., Johnson, W.E., Parker, H.S., Jaffe, A.E., and Storey, J.D. (2012). The sva package
for removing batch effects and other unwanted variation in high-throughput experiments.
Bioinforma. Oxf. Engl. *28*, 882–883. https://doi.org/10.1093/bioinformatics/bts034.

68. Fang, H., Knezevic, B., Burnham, K.L., and Knight, J.C. (2016). XGR software for enhanced
interpretation of genomic summary data, illustrated by application to immunological traits.
Genome Med. *8*, 129. https://doi.org/10.1186/s13073-016-0384-y.

69. Turner, C.T., Brown, J., Shaw, E., Uddin, I., Tsaliki, E., Roe, J.K., Pollara, G., Sun, Y., Heather,
J.M., Lipman, M., et al. (2021). Persistent T Cell Repertoire Perturbation and T Cell Activation in
HIV   After   Long   Term   Treatment.   Front.   Immunol.   *12*,   634489.
https://doi.org/10.3389/fimmu.2021.634489.

70. Jacomy, M., Venturini, T., Heymann, S., and Bastian, M. (2014). ForceAtlas2, a continuous
graph layout algorithm for handy network visualization designed for the Gephi software. PloS
One *9*, e98679. https://doi.org/10.1371/journal.pone.0098679.

71. Swindell, W.R., Xing, X., Stuart, P.E., Chen, C.S., Aphale, A., Nair, R.P., Voorhees, J.J., Elder,
J.T., Johnston, A., and Gudjonsson, J.E. (2012). Heterogeneity of inflammatory and cytokine
networks   in   chronic   plaque   psoriasis.   PloS   One   *7*,   e34594.
https://doi.org/10.1371/journal.pone.0034594.

72. Hulsen, T., de Vlieg, J., and Alkema, W. (2008). BioVenn - a web application for the comparison
and visualization of biological lists using area-proportional Venn diagrams. BMC Genomics *9*,
488. https://doi.org/10.1186/1471-2164-9-488.

73. Nusslein-Volhard, C. (2002). Zebrafish: A Practical Approach 1 edition. R. Dahm, ed. (Oxford
University Press).

74. Kroll, F., Powell, G.T., Ghosh, M., Gestri, G., Antinucci, P., Hearn, T.J., Tunbak, H., Lim, S.,
Dennis, H.W., Fernandez, J.M., et al. (2021). A simple and effective F0 knockout method for
rapid screening of behaviour and other complex phenotypes. eLife *10*, e59683.
https://doi.org/10.7554/eLife.59683.

75. Aggad, D., Mazel, M., Boudinot, P., Mogensen, K.E., Hamming, O.J., Hartmann, R., Kotenko,
S., Herbomel, P., Lutfalla, G., and Levraud, J.-P. (2009). The two groups of zebrafish virus-
induced interferons signal via distinct receptors with specific and shared chains. J. Immunol.
Baltim. Md 1950 *183*, 3924–3931. https://doi.org/10.4049/jimmunol.0901495.

76. Takaki, K., Davis, J.M., Winglee, K., and Ramakrishnan, L. (2013). Evaluation of the
pathogenesis and treatment of Mycobacterium marinum infection in zebrafish. Nat. Protoc. *8*,

1114–1124. https://doi.org/10.1038/nprot.2013.068.

77. van Leeuwen, L.M., van der Kuip, M., Youssef, S.A., de Bruin, A., Bitter, W., van Furth, A.M.,
and van der Sar, A.M. (2014). Modeling tuberculous meningitis in zebrafish using Mycobacterium
marinum. Dis. Model. Mech. *7*, 1111–1122. https://doi.org/10.1242/dmm.015453.

78. Benard, E.L., van der Sar, A.M., Ellett, F., Lieschke, G.J., Spaink, H.P., and Meijer, A.H. (2012).
Infection of zebrafish embryos with intracellular bacterial pathogens. J. Vis. Exp. JoVE.
https://doi.org/10.3791/3781.

79. Wilkinson, R.N., Elworthy, S., Ingham, P.W., and van Eeden, F.J.M. (2013). A method for high-
throughput PCR-based genotyping of larval zebrafish tail biopsies. BioTechniques *55*, 314–316.
https://doi.org/10.2144/000114116.

80. Stirling, D.R., Suleyman, O., Gil, E., Elks, P.M., Torraca, V., Noursadeghi, M., and Tomlinson,
G.S. (2020). Analysis tools to quantify dissemination of pathology in zebrafish larvae. Sci. Rep.
10, 3149. https://doi.org/10.1038/s41598-020-59932-1.

81. Sholl, D.A. (1953). Dendritic organization in the neurons of the visual and motor cortices of the
cat. J. Anat. *87*, 387–406.

82. van der Walt, S., Colbert, S.C., and Varoquaux, G. (2011). The NumPy Array: A Structure for
Efficient Numerical Computation. Comput. Sci. Eng. *13*, 22–30.
https://doi.org/10.1109/MCSE.2011.37.

83. van der Walt, S., Schönberger, J.L., Nunez-Iglesias, J., Boulogne, F., Warner, J.D., Yager, N.,
Gouillart, E., Yu, T., and scikit-image contributors (2014). scikit-image: image processing in
Python. PeerJ *2*, e453. https://doi.org/10.7717/peerj.453.

84. Meeker, N.D., Hutchinson, S.A., Ho, L., and Trede, N.S. (2007). Method for isolation of PCR-
ready genomic DNA from zebrafish tissues. BioTechniques *43*, 610, 612, 614.
https://doi.org/10.2144/000112619.

85. Labun, K., Guo, X., Chavez, A., Church, G., Gagnon, J.A., and Valen, E. (2019). Accurate
analysis of genuine CRISPR editing events with ampliCan. Genome Res. *29*, 843–847.
https://doi.org/10.1101/gr.244293.118.

ACKNOWLEDGEMENTS

We thank Michelle Berin and Victoria Dean (Clinical Research Nurses, UCL Division of Infection and

Immunity) and Mylah Ramirez (Research Nurse, Barts Health NHS Trust) for support with research

governance, participant recruitment and sample collection. We thank the UCL Zebrafish Facility staff,

particularly Heather Callaway, Jenna Hakkesteeg, Karen Dunford, Carole Wilson and Elise

Hitchcock for maintenance of the zebrafish lines used in this study, especially during the first wave

of the COVID-19 pandemic. We thank UCL Genomics for library preparation and sequencing of

samples for transcriptional profiling (www.ucl.ac.uk/child-health/research/genetics-and-genomic-

medicine/ucl-genomics). We thank Alex Lubin and Katie-Jo Miller for next generation sequencing of

zebrafish samples for genotyping. This work has benefited from the facilities and expertise of

CELPHEDIA-TEFOR, UAR2010 TEFOR Paris-Saclay (TEFOR Infrastructure - Investissement

d'avenir - ANR-II-INBS-0014) and from the Recombinant Protein Platform of the Institut Pasteur,

Paris.

GST is supported by a UK MRC Clinician Scientist Fellowship (MR/N007727/1). MN is supported by

the Wellcome Trust (207511/Z/17/Z). PME is supported by a Sir Henry Dale Fellowship jointly funded

by the Wellcome Trust and the Royal Society (105570/Z/14/Z). J-PL is supported by Fondation pour

la Recherche Medicale (grant EQU202203014646). MN and GST are also supported by NIHR

Biomedical Research Centre Funding to University College Hospitals NHS Foundation Trust and

University College London.

AUTHOR CONTRIBUTIONS

Conceived the study: GST, MN

Collected the data: ASS, BSMDDE, JR, AC, ET, GP, J-PL, GST

Provided resources or analysis tools: ASS, BSMDDE, JR, CTT, MCIL, HK, GP, PME, EMP, J-PL,

MN, GST

Performed the data analysis / interpretation: ASS, BSMDDE, JR, CTT, GP, PME, EMP, J-PL, MN,

GST

Prepared the manuscript draft: GST, ASS, BSMDDE

All authors reviewed and contributed to the final manuscript.

COMPETING INTERESTS

The authors declare no competing interests.

DATA AVAILABILITY

Human TST RNAseq data and peripheral blood RNAseq data from healthy individuals are already

available in the ArrayExpress repository under accession numbers E-MTAB-6816 and E-MTAB-

10022, respectively. Human peripheral blood data from TB patients and zebrafish RNAseq data will

be made available in ArrayExpress at the time of peer reviewed publication of the manuscript. Source

30

data for figure panels with fewer than 20 data points are available in Data S1.

CODE AVAILABILITY

The source code and manual for QuantiFish software used for analysis of bacterial burden and

dissemination in zebrafish larvae are available at https://github.com/DavidStirling/QuantiFish. The

ImageJ macro used to generate montages from the Hermes microscope images and source code

and manual for the Python script used for analysis of steady state cell numbers and cellular

recruitment in zebrafish are available at https://github.com/andreaszydloshein/FIJI-Image-to-Stack

and https://github.com/andreaszydloshein/Zytometer, respectively.

FIGURES

Figure 1. The steady state human peripheral blood transcriptome reflects immune responses

positively correlated with TB severity. (A) Frequency distribution of the correlation coefficients for

the relationship between the abundance of each of the 2620 transcripts which define the peripheral

blood transcriptome derived from 50 individuals with pulmonary tuberculosis (TB) and radiographic

disease severity. Coloured boxes highlight statistically significant correlations ($p < 0.05$).

(B) Reactome pathway enrichment among blood transcriptome genes whose expression is

statistically significantly correlated with radiographic TB disease severity; corr = correlated.

(C) Network diagram of statistically significant (FDR<0.05) upstream regulators (labelled nodes)

coloured by their molecular function, of target gene modules whose expression is positively

correlated with radiological TB severity. Size of the nodes for upstream regulators is proportional to

-Log10 adjusted p value. Nodes were clustered using the Force Atlas 2 algorithm in Gephi (version

0.9.2).

Figure 2. Reduced type I interferon activity in the TST transcriptome is associated with increased severity of human pulmonary TB disease. (A) Frequency distribution of the correlation coefficients for the relationship between the abundance of each of the 3222 transcripts within the TST transcriptome derived from 51 individuals with pulmonary TB and radiographic disease severity. Coloured boxes highlight statistically significant correlations (p<0.05). **(B, C)** Network diagrams of statistically significant (FDR<0.05) cytokines **(B)** and transcription factors **(C)** predicted to be upstream regulators (red) of target gene (blue) modules whose expression is negatively correlated with radiological TB severity. Size of the nodes for upstream regulators is proportional to -Log10 adjusted p value. Nodes were clustered using the Force Atlas 2 algorithm in Gephi (version 0.9.2). **(D, E)** The inverse relationship between average expression in each TST sample of two distinct, independently derived gene modules specific for type I interferon activity (Table S1) **(D)** with TB severity **(E)**. r values and p values were derived from two-tailed Spearman rank correlations. CXR = Chest x-ray, MΦ = Macrophage, KC = Keratinocyte.

Figure 3. Increased severity of *M. marinum* infection in *stat2* CRISPants. (A) Schematic representation of the human canonical type I interferon signalling pathway (left) which is highly conserved in zebrafish (right). **(B, C)** The average expression of two largely non-overlapping **(B)** type I interferon inducible gene modules derived from independent data (Table S1) in genome-wide mRNA sequencing data from whole wild type embryos four days post-intravenous infection with 400 colony forming units (cfu) of *M. marinum* (Mm) compared with uninfected (UI) siblings **(C)**. Data are from four independent experiments. **(D)** *stat2* CRISPant (*stat2*-/-) and control ribonucleoprotein (RNP) injected (*stat2*+/+) zebrafish larvae four days post intravenous infection with 400 cfu *M. marinum*. Scale bar = 250 μm. Dashed white lines indicate the outline of each larva. **(E)** Survival of control and *stat2* disrupted zebrafish larvae 1-4 days post infection with *M. marinum*. p value was derived from a log-rank (Mantel-Cox) test. **(F-H)** Comparison of integrated fluorescence (IF) (a surrogate for bacterial burden) **(F)**, number of bacterial foci **(G)** and spatial distribution of bacteria **(H)**, in *stat2* CRISPants compared to control RNP injected siblings. Each data point represents an

966   individual zebrafish larva, lines and error bars indicate the median and interquartile range. p values

967   were derived from two-tailed Mann-Whitney tests. Data are representative of four experiments.

968   dpi = days post-infection.

Figure 4. Reduced steady state neutrophil numbers in *stat2* CRISPants. (A) Representative

images of three day post-fertilisation (dpf) control (upper panel) and *stat2* CRISPant (lower panel)

Tg(mpeg1:mCherry) zebrafish larvae delineated by the dashed white lines. Scale bar = 250 μm.

(B) Integrated fluorescence (IF) as a surrogate for steady state macrophage numbers in three dpf

stat2 CRISPants compared to siblings injected with scrambled ribonucleoproteins (RNPs).

(C) Representative images of two dpf control (upper panel) and *stat2* CRISPant (lower panel)

Tg(mpx:eGFP) zebrafish larvae delineated by the dashed white lines. Scale bar = 250 μm.

(D) Quantitation of baseline neutrophil numbers (represented by IF) in two dpf *stat2* CRISPants and

negative control RNP injected siblings. Each data point represents an individual zebrafish larva, lines

and error bars indicate the median and interquartile range. p values were derived from two-tailed

Mann-Whitney tests. Data are from three independent experiments.

Figure 5. Neutrophil recruitment to the site of sterile injury is not *stat2* dependent.
(A) Representative images of eGFP-expressing neutrophils recruited to the site of injury 1, 6 and 24 hours following tailfin transection of three day post-fertilisation (dpf) *stat2* CRISPant *Tg(mpx:eGFP)* zebrafish larvae and scrambled ribonucleoprotein (RNP) injected controls. Scale bar represents 100 μm. The white dashes indicate the outline of the tailfin. **(B)** Distance of neutrophils from the injury site at 1, 6 and 24 hours post-wound (hpw), derived by identifying the Sholl circle in which the maximum integrated fluorescence (IF), a surrogate for highest cell numbers, was detected in *stat2* CRISPants and scrambled RNP injected siblings. **(C-D)** IF, a surrogate for total neutrophil numbers **(C)**, and IF at the wound site, representing neutrophil numbers localized to the tailfin transection **(D)** are shown at 1, 6 and 24 hours following injury. On scatter plots data points represent individual zebrafish larvae and lines and error bars the median and interquartile range. On box and whisker plots horizontal lines represent median values, box limits indicate the interquartile range and whiskers extend between the 5th and 95th percentiles. p values were derived from two-tailed Mann-Whitney tests. * = p<0.05. Data are from three independent experiments. px = Pixels.

Figure 6. Reduced macrophage recruitment to the site of sterile injury in *stat2* CRISPants. **(A)** Representative images of mCherry-expressing macrophages recruited to the site of tailfin transection by 6 and 24 hours, in three day post-fertilisation (dpf) *stat2* CRISPant *Tg(mpeg1:mCherry)* zebrafish embryos and controls. Scale bar represents 100 μm. The dashed white lines indicate the edge of the tailfin. **(B)** Comparison of the distance of macrophages from the site of injury at the indicated time points for *stat2* CRISPants and control RNP injected siblings. **(C)** Integrated fluorescence (IF) a surrogate for macrophage numbers at the site of tailfin transection is shown at 1, 6 and 24 hours post-wound (hpw). On scatter plots data points represent individual zebrafish larvae and lines and error bars the median and interquartile range. On box and whisker plots horizontal lines represent median values, box limits indicate the interquartile range and whiskers extend between the 5th and 95th percentiles. p values were derived from two-tailed Mann-Whitney tests. * = p<0.05. Data are from three independent experiments. px = Pixels.

1013

Figure 7. Reduced macrophage and neutrophil recruitment to *M. marinum* in *stat2* CRISPants.

(A) Representative images of mCherry-expressing macrophages recruited to the hindbrain (dashed white outline) 18 hours post-injection (hpi) of PBS or 200 colony forming units (cfu) *M. marinum* in two day post-fertilisation (dpf) *stat2* CRISPant *Tg(mpeg1:mCherry)* zebrafish larvae and scrambled ribonucleoprotein (RNP) injected controls. **(B)** Number of macrophages recruited to the hindbrain in response to PBS or *M. marinum* in *stat2* CRISPants and negative control RNP injected siblings. **(C)** Representative images of eGFP-expressing neutrophils recruited to the hindbrain (dashed white outline) 6 hours after PBS or *M. marinum* injection (200 cfu) in two dpf *stat2* CRISPant and control *Tg(mpx:eGFP)* zebrafish larvae. **(D)** Quantitation of neutrophils recruited to the site of *M. marinum* infection in *stat2* CRISPants and control siblings. Scale bars represent 100 μm. Data points represent individual zebrafish larvae and lines and error bars the median and interquartile range. p values were derived from two-tailed Mann-Whitney tests. * = $p<0.05$. Data are from three independent experiments.

1027

1028   **TABLES**

		TST*	Saline controls	Blood controls
Number		51	49	58
Age	(median and range)	30 (19-77)	28 (18-75)	36 (21-69)
Sex	Male	31 (61%)	19 (39%)	16 (28%)
	Female	20 (39%)	30 (61%)	42 (72%)
Ethnicity	White	21 (41%)	20 (41%)	44 (76%)
	Asian	15 (29%)	8 (16%)	9 (15%)
	Black	12 (24%)	7 (14%)	1 (2%)
	Mixed	2 (4%)	1 (2%)	4 (7%)
	South American	1 (2%)	11 (22%)	0
	Not recorded	0	2 (4%)	0
Intradermal injection site induration (mm)	(median and range)	20 (0-70)	0	NA
Days TB treatment before TST +/ saline	(median and range)	19 (0-30)	15 (0-28)**	NA
CXR severity score	(median and range)	30 (0-140)	15 (0-110)**	NA

1029

Table 1. Clinical and demographic data summary. Demographic characteristics and magnitude

of clinical induration of the skin at the site of TST or saline injection are summarised for all study

subjects. Duration of anti-tuberculous drug treatment at the time of sampling and radiographic

disease severity data are provided for individuals with pulmonary TB. *Peripheral blood samples

were also taken from 50 of these individuals with pulmonary TB. Saline samples were obtained from

17 individuals with pulmonary TB and 32 healthy participants who were people with cured or latent

TB, BCG vaccine recipients and healthy volunteers, described previously [10]. Control blood samples

from healthy individuals were described previously [13]. **Applies only to participants with active TB

receiving saline injections. CXR = chest x-ray.